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Abstract
Rho is a major small GTP-binding protein that is involved in the
regulation of various cell functions, including proliferation and
cell migration, through activation of multiple signaling molecules
in various types of cells. We studied its roles in synovial
fibroblasts (SFs) in patients with rheumatoid arthritis (RA) and
clarified its relevance to RA synovitis, with the following results.
1)We found that the thrombin receptor was overexpressed on
RA synovial fibroblasts (RA SFs) and that thrombin induced a
marked proliferation and progression of the cell cycle to the S
phase in these cells. 2)We also found that thrombin efficiently
activated Rho. 3)Rho activation and proliferation and the
progression of the cell cycle to the S phase were completely
blocked by p115RGS (an N-terminal regulator of the G-protein
signaling domain of p115RhoGEF) and by the C-terminal
fragments of Gα13 (an inhibitor of the interaction of receptors
with G13). 4)Thrombin induced the secretion of IL-6 by RA SFs,
but this action was blocked by p115RGS or Gα13. Our findings
show that the actions of thrombin on the proliferation of RA SFs,
cell-cycle progression to the S phase, and IL-6 secretion were
mainly mediated by the G13 and RhoGEF pathways. These
results suggest that p115RGS and Gα13 could be potent
inhibitors of such functions. A rational design of future
therapeutic strategies for RA synovitis could perhaps include
the exploitation of the Rho pathway to directly reduce the growth
of synovial cells.
Introduction
Rheumatoid arthritis (RA) is characterized by synovial pro-
liferation, neovascularization, and accumulation of inflam-
matory cells in inflamed joints. Synovial cells are markedly
activated by cytokines, adhesion molecules, and coagula-
tion factors, resulting in hyperplasia of the synovial tissue,
and the activated synovial cells produce inflammatory
cytokines and degradative enzymes. These pathological
processes in RA synoviocytes are tightly regulated by intra-
cellular signaling. The small GTPase Rho is a pivotal regu-
lator of several signaling pathways, including the
remodeling of actin cytoskeleton, transcriptional regulation,
and cell-cycle progression [1-4]. Like other regulatory
GTPases, Rho requires GDP/GTP exchange dependent
on guanine nucleotide exchange factors (GEFs) for its acti-
vation [5]. GEFs are critical regulators of Rho activation
and thereby control a variety of cellular responses such as
cell proliferation and cytokine production. However, the rel-
evance of Rho-mediated signaling to inflammatory proc-
esses in RA is largely unknown.
Among the various stimuli that activate the GEF–Rho path-
way, thrombin is the best-known activator through the fol-
lowing sequence of events: binding thrombin to protease-
activated receptor-1 including a thrombin receptor; activa-
tion of heterotrimeric G proteins Gq, Gi, and G12/13 [6-8];
activation of p115RhoGEF by the α subunit of G12/13;
binding of a Rho-specific GEF containing a Dbl homology
DMEM = Dulbecco's modified Eagle's medium; ELISA = enzyme-linked immunosorbent assay; FACS = fluorescence-activated cell sorter; FCS = 
fetal calf serum; Gα12-ct = the carboxy-terminal regions of Gα12; Gα13-ct = the carboxy-terminal regions of Gα13; GAP = GTPase-activating pro-
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clonal antibody; OA = osteoarthritis; p115RGS = regulator of G-protein signaling domain of p115RhoGEF; PBS = phosphate-buffered saline; RA = 
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domain to Rho; and activation of Rho by GDP/GTP
exchange [9-12].
Recent studies have indicated that Rho regulates cellular
functions in inflammatory cells [13-16]. Rho GTPases have
been implicated in the regulation of cell proliferation and IL-
2 production in T cells [13,17,18]. RA is a representative
inflammatory disease and is characterized by accumulation
of T cells and proliferation of synovial fibroblasts [19,20].
Although many molecules, including inflammatory
cytokines such as IL-1, tumor necrosis factor (TNF), and IL-
6 and growth factors, have been implicated as pathogenic
factors in RA, the coagulation system is also involved in the
inflammatory processes in RA synovitis. High levels of vari-
ous clotting and fibrinolytic factors such as thrombin are
found in the synovial fluid of patients with RA [21-24], and
high concentrations of thrombin are detected in RA syno-
vial tissue [25,26]. Moreover, thrombin promotes chemo-
taxis and adhesion of inflammatory cells such as
lymphocytes and the production of various proinflammatory
molecules [25,27,28]. Thrombin may therefore play an
important pathological role in RA synovitis.
The aim of the present study was to determine the role of
Rho-mediated signaling in the regulation of synovial prolif-
eration and cytokine production in RA SFs. The results indi-
cate that thrombin stimulation induces proliferation and IL-
6 secretion by RA SFs through G13 and Rho pathways
and suggest that the G13–GEF–Rho pathway plays an
important role in the RA inflammatory process.
Materials and methods
The study protocol was approved by the Human Ethics
Review Committee of the University of Occupational and
Environmental Health, Japan, and we obtained a signed
consent form from each subject before taking tissue sam-
ples used in the present study.
Synovial tissues and culture of synovial fibroblasts
Synovial tissues were obtained from five women (aged 45
to 66 years) with active RA or osteoarthritis (OA) whose
disease had been diagnosed according to the criteria of
the American College of Rheumatology [29-32] and who
were treated by joint replacement surgery. All the enrolled
patients with RA had more than six swollen joints, more
than three tender joints, and an erythrocyte sedimentation
rate (Westergren) of >28 mm/hour.
Samples were dissected under sterile conditions in PBS
and were immediately prepared for culture of fibroblast-like
synovial cells. Briefly, the tissue samples were minced into
small pieces and digested with collagenase (Sigma
Aldrich, Tokyo, Japan) in serum-free DMEM (Gibco BRL,
Grand Island, NY, USA). The cells were filtered through a
nylon mesh and then were washed extensively and sus-
pended in DMEM supplemented with 10% FCS (Bio-Pro,
Karlsruhe, Germany) and streptomycin/penicillin (10 units/
ml; Sigma Aldrich). Finally, isolated cells were seeded in
25-cm2 culture flasks (Falcon, Lincoln Park, NJ, USA) and
cultured in a humidified 5% CO2 atmosphere. After over-
night culture, nonadherent cells were removed and incuba-
tion of adherent cells was continued in fresh medium. At
confluence, the cells were trypsinized, passaged at a 1:3
split ratio, and recultured. The medium was changed twice
each week, and the cells were used after 2 to 5 passages.
We characterized cultured synovial cells derived from the
synovium of RA patients. The cells were spindle-shaped
and grew in a cobblestone pattern. Flow cytometric analy-
sis of these cells indicated that they lacked macrophage
markers such as major-histocompatibility-complex class II
antigens CD14 and CD11b (data not shown). Thus, RA
synovial cells are type B synovial-fibroblast-like cells.
Materials
Human thrombin was purchased from Sigma Aldrich. The
following mAbs were used: fluorescein-isothiocyanate-con-
jugated control mAb anti-Thy 1.2 (Becton Dickinson, San
Jose, CA, USA) and antithrombin receptor mAb ATAP2
(Santa Cruz Biotechnology, Santa Cruz, CA, USA). A Rho
activation kit containing glutathione S-transferase (GST)-
Rhotekin-Rho-binding domain (RBD) (GST-RBD) beads
was purchased from Cytoskeleton (Denver, CO, USA).
Adenoviral infection
Recombinant adenoviruses encoding green-fluorescent
protein (GFP), the C-terminal regions of Gα12 (Gα12-ct),
the C-terminal regions of Gα13 (Gα13-ct), and the regula-
tor of the G-protein signaling domain of p115RhoGEF
(p115RGS) were produced as described previously [33].
RA SFs were plated onto a six-well culture dish and cul-
tured in DMEM containing 10% FCS. After 24 hours, the
cells were infected with recombinant adenoviruses at a
multiplicity of infection of 30 for 1 hour at 37°C. Cells
infected or not infected with adenovirus were then starved
in DMEM with 1% FCS and cultured for an additional 48
hours before treatment. Under these conditions, infection
with adenoviruses coding for GFP made almost 100% of
cells GFP-positive. None of these vectors produced cyto-
toxic effects on RA SFs until 96 hours after infection, as
confirmed by trypan blue staining (data not shown).
Flow microfluorometry
Staining and flow-cytometric analysis of RA SFs were con-
ducted by standard procedures, as described previously
[34], using a FACScan (Becton Dickinson, Mountain View,
CA, USA). Briefly, cells (2 × 105) were incubated with flu-
orescein-isothiocyanate-conjugated negative control mAb
anti-Thy-1.2 or antithrombin receptor mAb at saturating
concentrations in fluorescence-activated cell sorter
(FACS) medium consisting of Hanks' balanced salt solu-Available online http://arthritis-research.com/content/7/3/R476
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tion (Nissui, Tokyo, Japan), 0.5% human serum albumin
(Mitsubishi Pharma, Osaka, Japan), and 0.2% NaN3 (Sigma
Aldrich) for 30 min at 4°C. After three washes in FACS
medium, the cells were analyzed with the FACScan. Cell-
surface antigens on single cells were quantified using
standard beads, QIFKIT (Dako Japan, Kyoto, Japan), as
described previously [35,36]. The data were used to con-
struct the calibration curve of mean fluorescence intensity
versus antibody-binding capacity. The cell specimen was
analyzed on the FACScan and antibody-binding capacity
calculated by interpolation on the calibration curve. When
green-fluorescence laser detection was set at 450 nm in
the FACScan used, antibody-binding capacity = 414.45 ×
exp (0.0092 × Mean fluorescence intensity) (R2 =
0.9999). Subsequently, specific antibody-binding capacity
was obtained after corrections for background, apparent
antibody-binding capacity of the negative control mAb anti-
Thy-1.2. The specific antibody-binding capacity is the mean
number of accessible antigenic sites per cell, referred to as
antigen density and expressed in sites/cell.
Proliferation assay
RA SFs (1 × 104) infected with or free of adenoviruses
were seeded and incubated in 96-well flat-bottomed micro-
filter plates (Costar, Cambridge, MA, USA) in DMEM con-
taining 1% FCS for 48 hours at 37°C and were then
stimulated with the indicated amount of thrombin. At 24
hours after the thrombin stimulation, cells were stained with
TetraColor One (Seikagaku, Tokyo, Japan) including tetra-
zolium and an electron-carrier mixture for detecting cell pro-
liferation. After the cells had been stained in this way for 1
hour at 37°C, the optical density value of each well was
measured using an ELISA plate reader at 450 nm.
Cell-cycle analysis
RA SFs infected with or free of adenoviruses were cultured
for 48 hours in DMEM containing 1% FCS and then stimu-
lated with the indicated amount of thrombin. At 24 hours
after thrombin stimulation, the cells were collected, washed
with PBS, and fixed in 70% ethanol for 2 hours at 4°C. After
treatment of cells with 10 µg/ml ribonuclease (Wako,
Osaka, Japan) for 15 min at 37°C, the cells were stained
with 50 µg/ml propidium iodide (Sigma Aldrich) for 2 min-
utes. The DNA content was subsequently measured by
FACScan.
Rho activation assay
Rho activation was determined by a pull-down assay using
GST-RBD beads [37,38]. Forty-eight hours after adenovi-
rus infection, RA SFs were stimulated with 10 units/ml
Figure 1
Overexpression of thrombin receptor on SFs from patients with RA Overexpression of thrombin receptor on SFs from patients with RA. (a) Histograms representing thrombin receptor expression on synovial fibrob-
lasts (SFs) from rheumatoid arthritis (RA) and osteoarthritis (OA) patients. Cells were stained with the antithrombin receptor mAb ATAP2. Flow-cyto-
metric analyses were performed using FACScan. Open histograms represent the number of cells stained with ATAP2 in each logarithmic scale on a 
fluorescence amplifier. Shaded histograms represent profiles of anti-Thy1.2 mAb as a negative control. (b) Comparison of thrombin receptor expres-
sion in RA and OA SFs. The expression of thrombin receptor was analyzed by FACScan. Each value represents the number of molecules expressed 
per cell, calculated using standard QIFKIT beads from five similar experiments, as described in Materials and methods. Data are expressed as mean 
± standard deviation for five independent donors. FACS, fluorescence-activated cell sorter. **P < 0.01.Arthritis Research & Therapy    Vol 7 No 3    Nakayamada et al.
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thrombin, quickly washed with ice-cold Tris-buffered saline,
and lysed in 500 µl of lysis buffer (50 mM Tris, pH 7.5, 10
mM MgCl2, 0.5 M NaCl, 1% Triton X-100, 0.5% sodium
deoxycholate, 0.1% SDS, 500 µg/ml tosyl arginine methyl
ester, and 10 µg/ml each of leupeptin and aprotinin). Cell
lysates were immediately centrifuged at 8,000 rpm at 4°C
for 5 min and equal volumes of lysates were incubated with
30 µg GST-RBD beads for 1 hour at 4°C. The beads were
washed twice with wash buffer (in mmoles: 25 Tris, pH 7.5;
30 MgCl2; 40 NaCl), and bound Rho was eluted by boiling
each sample in Laemmli sample buffer. Eluted samples
from the beads and total cell lysate were then electro-
phoresed on 12% SDS–PAGE gels, transferred to nitro-
cellulose, blocked with 5% nonfat milk, and analyzed by
western blotting using a polyclonal anti-Rho antibody.
Statistical analysis
Data are expressed as mean ± standard deviation (SD) of
the number of indicated patients. Differences from the con-
trol were examined for statistical significance by the Mann–
Whitney U test. A P value less than 0.05 denoted the pres-
ence of a statistically significant difference.
Results
High expression of thrombin receptor on RA SFs
First, we assessed the expression of thrombin receptor on
synovial fibroblasts using FACScan. Fig. 1a shows the his-
togram of thrombin receptor expressed on RA and OA syn-
ovial fibroblasts. Although thrombin receptor was
expressed on both types of synovial fibroblasts, its level
was significantly higher in RA than OA fibroblasts (Fig. 1b).
These results were identified in synovial fibroblasts from
patients with RA and OA (n = 5 each).
Thrombin induces synovial proliferation and S-phase 
progression of the cell cycle in RA SFs
To assess the effect of thrombin on the proliferation of RA
SFs, we performed proliferation assay and cell-cycle analy-
sis. After cells were starved for 48 hours in DMEM contain-
ing 1% FCS, cells were stimulated with the indicated
amount of thrombin for 24 hours. Thrombin significantly
induced cell proliferation in a dose-dependent manner (Fig.
2a). As shown in Fig. 2b, the vast majority of the starved
cells existed at the propidium-iodide-low G0/G1 phase and
showed little progression to S phase. However, thrombin
Figure 2
Thrombin induces synovial proliferation and progression to S phase in RA SFs Thrombin induces synovial proliferation and progression to S phase in RA SFs. Cells were cultured for 48 hours in DMEM containing 1% FCS and 
then stimulated with the indicated amount of thrombin. For the proliferation assay, at 24 hours after thrombin stimulation, cells were stained with Tet-
raColor One including tetrazolium and electron-carrier mixture for detecting cell proliferation. The optical density (OD) was measured by ELISA plate 
reader at 450 nm. For analysis of the cell cycle, at 24 hours after thrombin stimulation, cells were collected, washed with PBS, and fixed in 70% eth-
anol for 2 hours at 4°C. After treatment of cells with 10 µg/ml ribonuclease for 15 min at 37°C, fixed cells were stained with 50 µg/ml propidium 
iodide for 2 min. The DNA content was subsequently measured by FACScan fluorescence-activated cell sorter. (a) Dose-dependent proliferation of 
synovial fibroblasts (SFs) from rheumatoid arthritis (RA) patients. The OD was measured by ELISA plate reader at 450 nm. (b) Histogram represent-
ing the cell cycle in RA SFs, as detected by FACScan. (c) Dose-dependent S-phase progression of the cell cycle in RA SFs. Numbers represent the 
percentage of cells exhibiting mean channel fluorescence (FL2-H) in the S/G2/M phase of the cell. Data are expressed as mean ± standard deviation 
for five experiments, using five independent donors. **P < 0.01 in comparison with the value found without thrombin stimulation.Available online http://arthritis-research.com/content/7/3/R476
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significantly increased the S/G2/M phase of the cell in a
dose-dependent manner (Fig. 2b,c). The maximum effects
of thrombin on cell proliferation and progression to S phase
were noted at 10 units/ml. These results indicate that
thrombin acts as an important stimulator of RA synovial
proliferation.
We next compared cell growth and the cell cycle of RA SFs
w i t h  t h o s e  o f  O A  S F s .  A s  shown in Fig. 3a, thrombin
induced cell growth and cell-cycle progress in both RA and
OA SFs, whereas unstimulated cells did not proliferate
well. However, thrombin-induced proliferation of RA SFs
was significantly higher than that of OA SFs after incuba-
tion for 24 or 48 hours. As shown in Fig. 3b, thrombin
induced cell-cycle progress to S phase in both RA and OA
SFs, but the responses of RA SFs were significantly higher
than those of OA SFs after 24 hours of incubation.
Involvement of small GTP-binding protein Rho activation 
in thrombin-induced signaling in RA SFs
Thrombin is known to bind to protease-activated receptor-
1 such as thrombin receptor, and binding of thrombin to
receptors leads to activation of the G protein Gα13 and
induces activation of p115RhoGEF, a Rho-specific GEF,
and thereby activates Rho [9-12]. We measured Rho acti-
vation and its inhibition in RA SFs using the GST-Rhotekin
fusion protein. We used the C-terminal regions of Gα12
and Gα13, which inhibit Gα12 and Gα13 from coupling
with each receptor, or the regulator of the G-protein signal-
ing domain of p115RhoGEF, which inhibits endogenous
p115RhoGEF function by blocking the interaction of
p115RhoGEF with Gα12/13 and by its GTPase-activat-
ing-protein activity on Gα12/13 [33,39,40]. After adenovi-
ral infection, cells were stimulated with 10 units/ml
thrombin, and the lysates from cells were incubated with
Rhotekin bound to GST beads to determine Rho activation.
As shown in Fig. 4, thrombin stimulation increased the
amount of activated Rho in RA SFs infected or not infected
with adenoviruses encoding control vector, suggesting that
thrombin activates Rho in RA SFs. However, the expression
of Gα13-ct or p115RGS completely prevented thrombin-
induced Rho activation (Fig. 4). These results suggest that
Rho is involved in signaling via thrombin-stimulation, which
leads to synovial proliferation.
Involvement of G protein Gα13 and Rho-GEF in 
thrombin-induced proliferation of RA SFs
Thrombin (10 unit/ml) significantly induced synovial prolif-
eration and S-phase progression in RA SFs infected or not
infected with adenoviruses encoding control vector and
Figure 3
Effects of thrombin on proliferation and cell cycle in SFs from RA and OA Effects of thrombin on proliferation and cell cycle in SFs from RA and OA. Cells were cultured for 48 hours in DMEM containing 1% FCS and then 
stimulated with 10 units/ml thrombin. (a) Time-course of proliferation of synovial fibroblasts (SFs) from patients with rheumatoid arthritis (RA) (dark 
symbols) and patients with osteoarthritis (OA) (light symbols). Continuous lines, thrombin-stimulated cells; dotted lines, unstimulated cells. The opti-
cal density (OD) was measured by ELISA plate reader at 450 nm. (b) Comparison of cell cycle in RA SFs and OA SFs. Numbers represent the per-
centage of cells exhibiting mean channel fluorescence (FL2-H) in the S/G2/M phase of the cell-division cycle. Data are expressed as mean ± 
standard deviation of five experiments, using five independent donors. **P < 0.01.Arthritis Research & Therapy    Vol 7 No 3    Nakayamada et al.
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Gα12-ct (Fig. 5a,b). In contrast, thrombin failed to induce
both cell proliferation and S-phase progression in RA SFs
expressing Gα13-ct and p115RGS (Fig. 5a,b). These data
suggest that Gα13 (but not Gα12) and RhoGEF are
involved in signaling via thrombin-stimulation, which leads
to synovial proliferation.
Induction of IL-6 secretion via Rho-mediated signaling in 
RA SFs
Finally, we assessed IL-6 secretion by RA SFs, using
ELISA. Fig. 6 shows the concentrations of IL-6 in superna-
tants of thrombin-stimulated RA SFs. Stimulation with 10
units/ml thrombin significantly increased IL-6 secretion at 6
hours (Fig. 6b), and this effect was dose-dependent (Fig.
6a). The same dose of thrombin produced a significant
induction of IL-6 secretion by RA SFs infected or not
infected with adenoviruses encoding control vector (Fig.
6c). However, the thrombin-induced IL-6 secretion in RA
SFs transfected with Gα12-ct and Gα13-ct was partially
reduced and that in RA SFs expressing p115RGS was
markedly inhibited (Fig. 6c). These results suggest that
thrombin-induced IL-6 secretion by RA SFs is mainly medi-
ated through RhoGEF.
Discussion
The multiple functions of synovial cells including prolifera-
tion, apoptosis, adhesion, and cytokine production are
induced by intracellular signaling, which plays a pivotal role
in the pathological processes of RA, a representative
inflammatory disease. Among the signaling molecules, we
document here the relevance of Rho to the pathogenesis of
RA synovitis, based on the following results: high expres-
sion of thrombin receptor on RA SFs and thrombin mark-
edly increased the proliferation of these cells and
progression of the cell cycle to S phase; thrombin induced
the activation of Rho; Rho activation as well as proliferation
and S-phase progression were completely blocked by
either p115RGS or Gα13-ct; and thrombin-induced IL-6
secretion was also reduced by p115RGS and Gα13-ct.
Rho is activated by the G12/13 family of heterotrimeric
GTP-binding proteins through the stimulation of GEF activ-
ity of p115RhoGEF [12,39]. However, p115RhoGEF can
activate as well as inhibit Rho signaling after stimulation of
protease-activated receptor-1 [9,41]. p115RhoGEF also
contains the regulator of G-protein signaling (RGS) domain
at its N terminus, through which it interacts with Gα12/13
and functions as a GTPase-activating protein for G12/13
[39,42]. Furthermore, several groups have reported that C-
terminal fragments of Gα12 and Gα13 can inhibit the inter-
action of receptors with G12 and G13, respectively
[33,40,43]. Therefore, we used p115RGS domains and C-
terminal fragments of Gα subunits as inhibitors to analyze
Gα12- and Gα13-mediated signaling pathways. Using the
N-terminal RGS domain of p115RhoGEF, we observed
that thrombin activated Rho-dependent signaling and
induced synovial proliferation via the G13 pathway.
Previous studies postulated that local fibrin deposition pro-
motes inflammation and tissue destruction, based on the
findings of activation of the coagulation system and local
generation of fibrin in inflamed arthritic joints [25,44]. Fur-
thermore, recent studies indicate that the coagulation sys-
tem is closely associated with the inflammation of RA. The
level of thrombin, a ligand for G13, is markedly increased in
the synovial fluid and tissue of RA patients, compared with
Figure 4
Inhibition of thrombin-induced Rho activation by expression of Gα13-ct  and p115RGS in RA synovial fibroblasts Inhibition of thrombin-induced Rho activation by expression of Gα13-ct 
and p115RGS in RA synovial fibroblasts. Rheumatoid arthritis (RA) 
synovial fibroblasts (SFs) were or were not infected with adenoviruses 
encoding green-fluorescent protein (GFP) (control vector), the C-termi-
nal regions of Gα13 (Gα13-ct), or P115RGS. Cells that were not 
infected with adenovirus were incubated in the medium alone. Cells 
were then cultured for 48 hours in DMEM containing 1% FCS, then 
stimulated with 10 units/ml thrombin for 1 minute or were loaded with 
GTPγS (positive control), after which they were lysed to measure Rho 
activity. Rho activity is indicated by the amount of Rho bound by the 
Rhotekin-Rho-binding domain (RBD) (top). The percentage of acti-
vated Rho (graph) is expressed as a ratio relative to 4% of total Rho 
(4% of total protein used in the RBD bead pull-down experiments). 
Results are representative of three experiments. Western blot analysis 
confirmed that equal amounts of total Rho were used for the pull-down 
assay under each condition (data not shown). (-), cells without infec-
tion; p115RGS, regulator of G-protein signaling domain of p115Rho 
guanine nucleotide exchange factor.Available online http://arthritis-research.com/content/7/3/R476
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those of OA patients, and significantly correlates with RA
activity [24]. Our results also indicated that the expression
of the thrombin receptor was significantly higher in RA than
OA synovial fibroblasts. Since the expression of thrombin
receptor is up-regulated by thrombin itself, it is conceivable
that up-regulation of thrombin receptor in RA SFs is a nat-
ural consequence of exposure to extravasated plasma
thrombin and tissue remodeling during the inflammatory
response [22,44,45]. Since thrombin induced cell growth
and cell-cycle progress of both RA and OA SFs, thrombin-
mediated activation of fibroblasts may not be specific for
RA SFs. However, responses of RA SFs to thrombin were
significantly higher than those of OA SFs, suggesting that
the thrombin–Rho pathway could be activated in RA SF.
In the present study, we observed failure of thrombin to
induce both cell proliferation and S-phase progression in
RA SFs that expressed Gα13-ct and p115RGS, but not
Gα12-ct. These data suggest that G13 and p115RhoGEF,
which is directly stimulated by G13, are involved in signal-
ing via thrombin-stimulation, subsequent Rho activation,
and synovial proliferation.
IL-6 plays an important role in the pathogenesis of RA [46-
51], since it is induced by a variety of stimuli such as IL-1
and TNF, is produced abundantly in RA synovium, and is
detected at high concentrations in the synovial fluid and
serum of RA. Among the various inflammatory cytokines,
production of IL-1α, IL-1β, and TNF-α from RA SFs did not
change after thrombin stimulation, as reported previously
[25]. The obtained results showed that thrombin markedly
induced IL-6 secretion from RA SFs. The thrombin-induced
IL-6 secretion was completely inhibited in RA SFs express-
ing p115RGS, whereas it was partially suppressed in the
cells that expressed Gα12-ct and Gα13-ct, suggesting the
possible existence of another pathway for the activation of
RhoGEF during IL-6 secretion in RA SFs.
Considering these findings all together, we conclude that
Rho plays a key role in synovial proliferation, S-phase cell-
cycle progression, and IL-6 secretion by thrombin-stimu-
lated RA SFs during the pathological process of synovial
inflammation. Furthermore, because p115RGS and Gα13
appear to be potent inhibitors of these cellular functions by
targeting the thrombin–G13–GEF–Rho pathway, a rational
Figure 5
G13 and Rho signaling in thrombin-mediated synovial proliferation and S-phase progression in RA SFs G13 and Rho signaling in thrombin-mediated synovial proliferation and S-phase progression in RA SFs. Rheumatoid arthritis (RA) synovial fibrob-
lasts (SFs) infected or not infected with adenoviruses encoding GFP (control vector), the C-terminal regions of Gα12 (Gα12-ct), Gα13-ct, or 
p115RGS were cultured for 48 hours in DMEM containing 1% FCS and then stimulated with 10 units/ml thrombin. At 24 hours after the thrombin 
stimulation, proliferation assay and cell-cycle analysis of RA SFs were performed. (a) Effect of Rho signaling inhibition on thrombin-induced cell pro-
liferation. Numbers represent the optical density (OD) as measured by ELISA plate reader at 450 nm. (b) Effect of Rho signaling inhibition on 
thrombin-induced cell-cycle progression. Numbers represent the percentage of cells that exhibited mean channel fluorescence (FL2-H) in the S/G2/
M phase. Data are expressed as mean ± standard deviation of five experiments, using five independent donors. (-), cells without infection; 
p115RGS, regulator of G-protein signaling domain of p115Rho guanine nucleotide exchange factor. *P < 0.05, **P < 0.01, in comparison with 
thrombin stimulation.Arthritis Research & Therapy    Vol 7 No 3    Nakayamada et al.
R483
design of future therapeutic strategies for RA synovitis
could perhaps include the exploitation of the Rho pathway
to directly reduce synovial cell growth in vivo.
Conclusion
Our results indicate that stimulation with thrombin induced
proliferation and IL-6 secretion by RA SFs through G13
and Rho pathways and suggest that the G13–GEF–Rho
pathway plays an important role in the RA inflammatory
process. A rational design of future therapeutic strategies
for RA synovitis could perhaps include the exploitation of
the Rho pathway to directly reduce synovial cell growth.
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